Tobacco consumption and lung cancer

  • Dietrich Hoffmann
  • Ilse Hoffmann
Part of the Cancer Treatment and Research book series (CTAR, volume 72)


In 1912, Adler asked in the introduction to his book Primary Malignant Growth of the Lungs and Bronchi, ‘Is it worthwhile to write a monograph on the subject of primary malignant lung tumors?’ He concluded, ‘There is nearly complete concensus of opinion that primary malignant neoplasms of the lungs are among the rarest forms of disease’ [1]. In the following 70 years, however, there was a dramatic increase of primary lung cancer throughout the world. By 1985, lung cancer was the most frequently occurring cancer worldwide, with an estimated 896,000 new cases accounting for 11.8% of all cancer cases [2]. Figures 1 and 2 present the increase of lung cancer incidence in men in eight developed countries, namely, the U.S.A., the United Kingdom, West Germany, and France, and Canada, Italy, Sweden, and Japan, respectively [3–14]. In the former U.S.S.R., lung cancer rose from about 31,400 reported cases in males and 8,800 in females in 1965 to 75,000 and 16,700, respectively, in 1984 [15]. In the U.S.A., lung cancer has been the leading cause of death from cancer in men since about 1960 and in women since about 1987 (figures 3 and 4).


Lung Cancer Pulmonary Adenocarcinoma Carcinogenic PAHs Mainstream Smoke Total Particulate Matter 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Adler I. 1912. Primary Malignant Growths of the Lungs and Bronchi. Longmans, Green & Co.: New York.Google Scholar
  2. 2.
    Parkin DM, Pisani P, Ferlay J. 1993. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 54:594–606.PubMedCrossRefGoogle Scholar
  3. 3.
    Silverberg E, Holleb AI. 1974. Cancer around the world, 1964–65/. CA Cancer J Clin 21:26–27.Google Scholar
  4. 4.
    Silverberg E, Holleb AI. 1971. Cancer around the world, 1966–67. CA Cancer J Clin 24:16–17.Google Scholar
  5. 5.
    Silverberg E. Holleb AI. 1975. Cancer around the world, 1968–69. CA Cancer J Clin 25:16–17.Google Scholar
  6. 6.
    Silverberg E, Holleb AI. 1976. Cancer around the world, 1970–71. CA Cancer J Clin 26:26–27.Google Scholar
  7. 7.
    Silverberg E, Holleb AI. 1978. Cancer around the world, 1972–73. CA Cancer J Clin 28:28–29.Google Scholar
  8. 8.
    Silverberg E, Holleb AI. 1980. Cancer around the world, 1974–75. CA Cancer J Clin 30:34–35.Google Scholar
  9. 9.
    Silverberg E, Holleb AI. 1982. Cancer around the world, 1976–77. CA Cancer J Clin 32:26–27.CrossRefGoogle Scholar
  10. 10.
    Silverberg E, Holleb AI. 1984. Cancer around the world, 1978–79. CA Cancer J Clin 34:18–19.Google Scholar
  11. 11.
    Silverberg E, Holleb AI. 1986. Cancer around the world, 1980–81. CA Cancer J Clin 36:20–121.Google Scholar
  12. 12.
    Silverberg E, Holleb AI. 1988. Cancer around the world, 1982–83. CA Cancer J Clin 38:18–19.Google Scholar
  13. 13.
    Silverberg E, Holleb AI. 1989. Cancer around the world, 1984–86. CA Cancer J Clin 39:16–17.Google Scholar
  14. 14.
    Boring CC, Squires TS, Tong T. 1991. Cancer around the world, 1986–88. CA Cancer J Clin 43:22–23.Google Scholar
  15. 15.
    Zaridze DG, Gurevicius R. 1986. Lung cancer in the USSR: Patterns and trends. In Tobacco, A Major International Health Hazard, DG Zaridze and R Peto (eds.). IARC Sci Publ 74:87–101.Google Scholar
  16. 16.
    Wynder EL, Gori GB. 1977. Contribution of the environment to cancer incidence: An epidemiologic exercise. J Natl Cancer Inst 58:825–832.PubMedGoogle Scholar
  17. 17.
    Doll R, Peto R. 1981. The causes of cancer: Quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst 66:1193–1308.Google Scholar
  18. 18.
    Hammond EC, Horn D. 1958. Smoking and death rates — report on 44 months of follow-up of 187,783 men. I. Total mortality. JAMA 166:1159–1172.CrossRefGoogle Scholar
  19. 19.
    Hammond EC, Horn D. 1958. Smoking and death rates — report on 44 months of follow-up of 187,783 men. II. Death rates by cause. JAMA 166:1294–1308.CrossRefGoogle Scholar
  20. 20.
    Pershagen, G. 1990. Air pollution and cancer. In Complex Mixtures and Cancer Risk, H Vainio, M Sorsa, and AJ Michael (eds.). IARC Monogr 104:240–251.Google Scholar
  21. 21.
    Royal College of Physicians, London. 1962. Smoking and Health. Pitman: London.Google Scholar
  22. 22.
    U.S. Surgeon General. 1964. Smoking and Health. U.S. Public Health Service Publ. No. 1103, Washington, DC.Google Scholar
  23. 23.
    Zaridze DG, Peto R. 1986. Tobacco: A major international health hazard. IARC Sci Publ 74.Google Scholar
  24. 24.
    Shopland DR, Eyre H-J, Pechacek TF. 1991. Smoking-attributable cancer mortality in 1991: Is lung cancer now the leading cause of death among smokers in the United States? J Natl Cancer Inst 83:1142–1148.PubMedCrossRefGoogle Scholar
  25. 25.
    U.S. Surgeon General. 1989. Reducing the health consequences of smoking. Twenty five years of progress. U.S. Department of Health Human Services Publ No (CDC) 89–8411.Google Scholar
  26. 26.
    Lee PN. 1975. Tobacco consumption in various countries. Research Paper 6, 4th ed. Tobacco Research Council, London.Google Scholar
  27. 27.
    Cigarette consumption in various countries 1972–1992 (editorial). Tobacco J Int.Google Scholar
  28. 28.
    Wynder EL, Day E. 1961. Some thoughts on the causaition of chronic disease. JAMA 175:997–999.PubMedCrossRefGoogle Scholar
  29. 29.
    U.S. Surgeon General. 1982. The health consequences of smoking. Cancer. U.S. Departrent of Health Human Services Publ No (PHS) 82-50179.Google Scholar
  30. 30.
    International Agency for Research on Cancer. 1986. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Vol. 38, Tobacco Smoking. IARC: Lyon, France.Google Scholar
  31. 31.
    Kahn HA. 1966. The Dorn study of smoking and mortality among U.S. veterans: Report on eight and one-half years of observation. Natl Cancer Inst Monogr 19:1–125.PubMedGoogle Scholar
  32. 32.
    American Cancer Society. 1988. Cancer Facts and Figures. American Cancer Society: New York.Google Scholar
  33. 33.
    Leuchtenberger C, Leuchtenberger R. 1970. Effects of chronic inhalation of whole fresh smoke and its gas phase on pulmonary tumorigenesis in Snell’s mice. U.S. Atomic Energy Comm Symp Ser 21:329–346.Google Scholar
  34. 34.
    Dontenwill W, Chevalier H-J, Harke H-P, Lafrenz U, Rekzeh G, Schneider B. 1973. Investigations of the effects of chronic cigarette smoke inhalation in Syrian golden hamsters. J Natl Cancer Inst 51:1781–1832.PubMedGoogle Scholar
  35. 35.
    Wynder EL, Hoffmann D. 1967. Tobacco and Tobacco Smoke: Studies in Experimental Carcinogenesis. Academic Press: New York.Google Scholar
  36. 36.
    Brunnemann KD, Hoffmann D. 1991. Analytical studies on N-nitrosamines in tobacco and tobacco smoke. Recent Adv Tobacco Sci 17:71–112.Google Scholar
  37. 37.
    Stellman SD, Garfinkel L. 1989. Lung cancer risk is proportional to cigarette tar yield. Evidence from a prospective study. Prev Med 18:518–525.PubMedCrossRefGoogle Scholar
  38. 38.
    Zang E, Wynder EL. 1992. Cumulative tar exposure. A new index for estimating lung cancer risk among cigarette smokers. Cancer 70:69–76.PubMedCrossRefGoogle Scholar
  39. 39.
    Wynder EL, Graham EA. 1950. Tobacco smoking as a possible factor in bronchiogenic carcinoma. A study of six hundred and eighty four proved cases. JAMA 143:329–336.CrossRefGoogle Scholar
  40. 40.
    El-Torky M, El-Zeky F, Hall CJ. 1990. Significant changes in the distribution of histologic types of lung cancer. A review of 4928 cases. Cancer 65:2361–2367.PubMedCrossRefGoogle Scholar
  41. 41.
    Dodds L, Davis S, Polissar L. 1986. A population-based study of lung cancer incidence trends by histologic type, 1974–81. J Natl Cancer Inst 76:21–29.PubMedGoogle Scholar
  42. 42.
    Wu AH, Henderson BE, Thomas DC, Mack TM. 1986. Secular trends in histologic types of lung cancer. J Natl Cancer Inst 77:53–56.PubMedGoogle Scholar
  43. 43.
    Beard CM, Jedd MB, Woolner LB. 1988. Fifty-year trend in incidence rates of bronchiogenic carcinoma by cell type in Olmsted County, Minnesota. J Natl Cancer Inst 80:1404–1407.PubMedCrossRefGoogle Scholar
  44. 44.
    Devesa SS, Shaw GL, Blot WJ. 1991. Changing patterns of lung cancer incidence by histologic type. Cancer Epidemiol Biomarkers Prev 1:29–34.PubMedGoogle Scholar
  45. 45.
    Chaudhuri PK, Thomas PA, Walker MJ, Briele HA, Das Gupta TKD, Beattie CW. 1982. Steroid receptors in human lung cancer cytosols. Cancer Lett 16:327–332.PubMedCrossRefGoogle Scholar
  46. 46.
    Hebert JR, Miller DR, Toporoff ED, Teas J, Barone J. 1991. Black-white differences in United States Cancer Rates: A discussion of possible dietary factors to explain large and growing divergencies. Cancer Prev 1:141–156.Google Scholar
  47. 47.
    Brunnemann KD, Hoffmann D. 1974. The pH of tobacco smoke. Food Cosmet Toxicol 12:115–124.PubMedCrossRefGoogle Scholar
  48. 48.
    Armitage AK, Turner DM. 1970. Absorption of nicotine in cigarette and cigar smoke through the oral mucosa. Nature 226:1231–1232.PubMedCrossRefGoogle Scholar
  49. 49.
    Brunnemann KD, Hoffmann D. 1975. Chemical studies on tobacco smoke XXXIV. Gas Chromatographic determination of ammonia in cigarette and cigar smoke. J Chromatogr Sci 13:159–163.PubMedGoogle Scholar
  50. 50.
    Neurath G, Ehrake H. 1964. Untersuchungen über den Nitratgehalt des Tabaks. Beitr Tabakforsch 2:333–344.Google Scholar
  51. 51.
    Kotin P, Falk HL. 1963. Atmospheric factors in the pathogenesis of lung cancer. Adv Cancer Res 7:475–514.PubMedCrossRefGoogle Scholar
  52. 52.
    Dube MF, Green CR. 1982. Methods of collection of smoke for analytical purposes. Recent Adv Tobacco Sci 8:42–102.Google Scholar
  53. 53.
    Roberts DL. 1988. Natural tobacco flavor. Recent Adv Tobacco Sci 14:49–81.Google Scholar
  54. 54.
    Nakayama T, Kodama M, Nagata C. 1984. Generation of hydrogen peroxide and Superoxide anion radical from cigarette smoke. Gann 75:95–98.PubMedGoogle Scholar
  55. 55.
    Pryor W, Stone K. 1993. Oxidants in cigarette smoke. Radicals, hydrogen peroxide, peroxynitrate and peroxynitrite. Ann NY Acad Sci 686:12–28.PubMedCrossRefGoogle Scholar
  56. 56.
    Knekt P. 1993. Vitamin E and smoking and the risk of lung cancer. Ann NY Acad Sci 686:280–288.PubMedCrossRefGoogle Scholar
  57. 57.
    Chow CK. 1993. Cigarette smoking and oxidative damage in the lung. Ann NY Acad Sci 686:289–298.PubMedCrossRefGoogle Scholar
  58. 58.
    Green CR. 1977. Some relationship between tobacco leaf and smoke composition. Proc Am Chem Soc Symp Recent Advances in the Chemical Composition of Tobacco and Tobacco Smoke, New Orleans, LA, pp. 426–470.Google Scholar
  59. 59.
    Wahlberg I, Enzell CR. 1987. Tobacco isoprenoids. Natural Product Rep 4:237–276.CrossRefGoogle Scholar
  60. 60.
    Tso TC. 1990. Production, Physiology and Biochemistry of the Tobacco Plant. Ideals Inc., Beltsville, MD.Google Scholar
  61. 61.
    Russell MAH. 1980. The case for medium-nicotine, low-tar, low-carbon monoxide cigarettes. In A Safe Cigarette? GB Gori and FG Bock (eds.). Banbury Rep 3:297–310.Google Scholar
  62. 62.
    Herning RI, Jones RT, Bachman J, Mines AH. 1981. Puff volume increases when low-nicotine cigarettes are smoked. Br Med J 283:187–189.CrossRefGoogle Scholar
  63. 63.
    Kozlowski LT, Rickert WS, Pope MA, Robinson JC, Frecker RC. 1982. Estimating the yield to smokers of tar, nicotine, and carbon monoxide from the ‘lowest yield’ ventilated filter-cigarettes. Br J Addict 77:159–165.PubMedCrossRefGoogle Scholar
  64. 64.
    Haley NJ, Sepkovic DW, Hoffmann D, Wynder EL. 1985. Cigarette smoking as a risk factor for cardiovascular disease VI. Compensation with nicotine availability as a single variable. Clin Pharmacol Ther 38:164–170.PubMedCrossRefGoogle Scholar
  65. 65.
    Norman V. 1977. An overview of the vapor phase semi-volatile and nonvolatile components of cigarette smoke. Recent Adv Tobacco Sci 3:28–58.Google Scholar
  66. 66.
    Jenkins RW Jr, Goldey C, Williamson TG. 1985. Neutron activation analysis in tobacco and tobacco smoke studies: 2R1 cigarette composition, smoke transference and butt filtration. Beitr Tabakforsch 13:59–65.Google Scholar
  67. 67.
    Wittekindt W. 1986. Recommended plant protecting agents — current strategies in 22 important tobacco exporting countries. Beitr Tabakforsch 13:271–280.Google Scholar
  68. 68.
    Sheets TJ. 1991. Pesticides on tobacco: Perceptions and realities. Recent Adv Tobacco Sci 17:33–68.Google Scholar
  69. 69.
    Leffingwell JC, Leffingwell D. 1988. Chemical and sensory aspects of tobacco flavor — An overview. Recent Adv Tobacco Sci 14:169–218.Google Scholar
  70. 70.
    Perfetti TA, Gordon HH. 1985. Just noticeable difference studies of mentholated cigarette products. Tobacco Sci 29:57–66.Google Scholar
  71. 71.
    International Agency for Research on Cancer. 1976. Coumarin. IARC Monogr 10:113–119.Google Scholar
  72. 72.
    Dalbey WE, Nettesheim D, Griesemer R, Caton JE, Guerin MR. 1980. Chronic inhalation of cigarette smoke by 344 rats. J Natl Cancer Inst 64:383–390.PubMedGoogle Scholar
  73. 73.
    Hoffmann, D, Wynder EL. 1971. A study of tobacco carcinogenesis XI. Tumor initiators, tumor accelerators and tumor promoting activity of condensate fractions. Cancer 27:848–864.PubMedCrossRefGoogle Scholar
  74. 74.
    Dontenwill W, Chevalier HJ, Harke HPV, Klimisch HJ. 1976. Experimentelle Untersuchungen über die krebserzeugende Wirkung von Zigarettenrauch-Kondensaten an der Mâusehaut. VI. Mitteilung: Untersuchungen zur Fraktionierung von Zigarettenrauch-Kondensat. Z Krebsforsch 85:1655–1161.Google Scholar
  75. 75.
    Hecht SS, Thorne RL, Maronpot RR, Hoffmann D. 1975. A Study of Tobacco Carcinogenesis XIII. Tumor promoting subfractions of the weakly acidic fraction. J Natl Cancer Inst 55:1329–1336.PubMedGoogle Scholar
  76. 76.
    Van Duuren BL, Goldschmidt BM. 1976. Cocarcinogenic and tumor promoting agents in tobacco carcinogenesis. J Natl Cancer Inst 56:1237–1242.PubMedGoogle Scholar
  77. 77.
    Hecht SS, Carmella S, Mori H, Hoffmann D. 1981. Role of catechol as a major cocarcinogen in the weakly acidic fraction of smoke condensate. J Natl Cancer Inst 66:163–169.PubMedGoogle Scholar
  78. 78.
    Blacklock JW. 1957. The production of lung tumors in rats by 3,4-benzopyrene, methyl-cholanthrene and condensate from cigarette smoke. Br J Cancer 11:181–191.PubMedCrossRefGoogle Scholar
  79. 79.
    Deutsch-Wenzel R, Brune H, Grimmer G, Dettbarn G, Misfeld J. 1983. Experimental studies in rat lungs on the carcinogenicity and dose-response relationships of eight frequently occurring environmental polycyclic aromatic hydrocarbons. J Natl Cancer Inst 71:539–544.PubMedGoogle Scholar
  80. 80.
    Harley NH, Cohen BS, Tso TC. 1980. Polonium-210. A questionable risk factor in smoking-related carcinogenesis. Banbury Rep 3:93–104.Google Scholar
  81. 81.
    National Council on Radiation Protection and Measurement. 1987. Ionizing radiation exposure of the population of the United States. NCRP Rep 93, Bethesda, MD.Google Scholar
  82. 82.
    Doll R. 1971. Cancers related to smoking. Proc. 2nd World Conf. Smoking and Health. Pitman: London, pp. 10–23.Google Scholar
  83. 83.
    Bryant MS, Vineis P, Skipper PL, Tannenbaum SR. 1988. Hemoglobin adducts of aromatic amines: associations with smoking status and type of tobacco. Proc Natl Acad Sci USA 85:9788–9791.PubMedCrossRefGoogle Scholar
  84. 84.
    Bartsch H, Malaveille C, Friesen M, Kadlubar FF, Vineis F. 1993. Black (air-cured) and blond (flue-cured) tobacco cancer risk IV. Molecular dosimetry studies implicate aromatic amines as bladder carcinogens. Eur J Cancer, 1199–1207.Google Scholar
  85. 85.
    Hecht SS, Hoffmann D. 1989. The relevance of tobacco-specific nitrosamines to human cancer. Cancer Surv 8:273–294.PubMedGoogle Scholar
  86. 86.
    National Research Council. 1981. The Health Effects of Nitrate, Nitrite, and N-Nitroso Compounds. NRC: Washington, DC, chapter 7.Google Scholar
  87. 87.
    Rivenson A, Hoffmann D, Prokopczyk B, Amin S, Hecht SS. 1988. A study of tobacco carcinogenesis XLII. Induction of lung and pancreas tumors in F344 rats by tobacco-specific and Areca-derived N-nitrosamines. Cancer Res 48:6912–6917.PubMedGoogle Scholar
  88. 88.
    LaVoie EJ, Prokopczyk G, Rigotty J, Czech A, Rivenson A, Adams JD. 1987. Tumorigenic activity of the tobacco-specific nitrosamines 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) 4-(methylnitrosamino)-4-(3-pyridyl)-1-butanol (NNAL) and N′-nitrosonornicotine (NNN) on topical application to Sencar mice. Cancer Lett 37:277–283.PubMedCrossRefGoogle Scholar
  89. 89.
    Belinsky SA, Foley JF, White CM, Anderson MW, Maronpot R. 1990. Dose-response relationship between O6-methylguanine formation in Clara cells and induction of pulmonary neoplasia in the rat by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res 50:3772–3780.PubMedGoogle Scholar
  90. 90.
    Hoffmann D, Djordjevic MV, Rivenson A, Zang E, Desai D, Amin S. 1993. A study of tobacco carcinogenesis LI. Relative potencies of tobacco-specific N-nitrosamines as inducers of lung tumors in A/J mice. Cancer Lett 71:25–30.PubMedCrossRefGoogle Scholar
  91. 91.
    Guengerich FP, Shimada T. 1991. Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem Res Toxicol 4:391–407.PubMedCrossRefGoogle Scholar
  92. 92.
    Dipple A, Moschel RC, Bigger CAH. 1984. Polynuclear aromatic carcinogens. In Chemical Carcinogens, CE Searle (ed.). Am Chem Soc Monogr 182:41–163.Google Scholar
  93. 93.
    Yun C-H, Shimada T, Guengerich FP. 1992. Roles of human liver cytochrome P450 2C and 3A enzymes in the 3-hydroxylation of benzo(a)pyrene. Cancer Res 52:1868–1874.PubMedGoogle Scholar
  94. 94.
    Pellkonen O, Vahakangas KN, Nebert DW. 1980. Binding of polycyclic aromatic hydrocarbons to DNA. Comparison with mutagenesis and tumorigenesis. J Toxicol Environ Health 6:1009–1020.CrossRefGoogle Scholar
  95. 95.
    Hall M, Grover PL. 1990. Polycyclic hydrocarbons: metabolism, activation and tumor initiation. In Chemical Carcinogenesis and Mutagenesis, Vol. 1, CS Cooper and PL Grover (eds.). Berlin: Springer-Verlag, pp. 327–372.CrossRefGoogle Scholar
  96. 96.
    Perera P, Mayer J, Jaretzki A, Hearne S, Brenner D, Young TL, Fischman HK, Grimes M, Grantham S, Tang MX. 1989. Comparison of DNA adducts and sister chromatid exchange in lung cancer cases and controls. Cancer Res 49:4446–4451.PubMedGoogle Scholar
  97. 97.
    Hansen AM, Poulsen OM, Christensen JM. 1993. Determination of 1-hydroxypyrene in human urine by high-performance liquid chromatography. J Anal Toxicol 17:38–44.PubMedGoogle Scholar
  98. 98.
    Morse MA, Eklind K, Toussant M, Amin SG, Chung F-L. 1990. Characterization of a glucuronidc metabolite of 4-(methylnitrosamino)-1-(3-pyridyl)-l-butanone (NNK) and its dose-dependent excretion in the urine of mice and rats. Carcinogenesis 11:1819–1823.PubMedCrossRefGoogle Scholar
  99. 99.
    Hecht SS, Trushin N, Reid-Quinn CA, Burak ES, Jones AB, Southers JL, Gombar CT, Carmella SG, Anderson LM, Rice JM. 1993. Metabolism of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-l-butanone in the patas monkey: pharmacokinetics and characterization of glucuronide metabolites. Carcinogenesis 14:229–236.PubMedCrossRefGoogle Scholar
  100. 100.
    Foiles PG, Akerkar SA, Carmella SG, Kagan M, Stoner GD, Resau JH, Hecht SS. 1991. Mass spectrometric analysis of tobacco-specific nitrosamine-DNA adducts in smokers and nonsmokers. Chem Res Toxicol 4:364–368.PubMedCrossRefGoogle Scholar
  101. 101.
    Carmella SG, Akerkar S, Hecht SS. 1993. Metabolites of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in smokers’ urine. Cancer Res 53:721–724.PubMedGoogle Scholar
  102. 102.
    Davis BR, Whitehead JK, Gill ME, Lee PN, Butterworth AD, Rose JJ. 1975. Response of rat lung to tobacco smoke condensate or fractions derived from it administered repeatedly by intratracheal instillation. Br J Cancer 31:453–461.PubMedCrossRefGoogle Scholar
  103. 103.
    Saffiotti U, Montesano R, Sellakumar AR, Cefis F, Kaufman DG. 1972. Respiratory tract carcinogenesis induced in hamsters by different dose levels of benzo(a)pyrene and ferric oxide. J Natl Cancer Inst 49:1199–1204.PubMedGoogle Scholar
  104. 104.
    Weston A, Bowman ED, Carr P, Rothman N. Strickland PT. 1993. Detection of metabolites of polycyclic aromatic hydrocarbons in human urine. Carcinogenesis 14:1053–1055.PubMedCrossRefGoogle Scholar
  105. 105.
    Alexandrov K, Rojas M, Geneste O, Castegnaro M, Camus A-M, Petruzzelli S, Giuntini C, Bartsch H. 1992. An improved fluorometric assay for dosimetry of benzo(a)pyrene diol-epoxide-DNA adducts in smokers’ lung: Comparisons with total bulky adducts and aryl hydrocarbon hydroxylase activity. Cancer Res 52:6248–6253.PubMedGoogle Scholar
  106. 106.
    Reynolds SH, Anna CK, Brown KC, Wiest JS, Beattie EJ, Pero RW, Iglehart JD, Anderson MW. 1991. Activated protooncogenes in human lung tumors from smokers. Proc Natl Acad Sci USA 88:1085–1089.PubMedCrossRefGoogle Scholar
  107. 107.
    Husgafvel-Pursiainen K, Hackman P, Ridanpäà M, Anttila S, Karjalainen A, Partanen T, Taikina-Aho O, Heikkila L, Vainio H. 1993. K-ras mutations in human adenocarcinoma of the lung: association with smoking and occupational exposure to asbestos. Int J Cancer 53:250–256.PubMedCrossRefGoogle Scholar
  108. 108.
    Chiba I, Takahashi T, Nau MM, D-Amico A, Curiel DT, Mitsudomi T, Buckhagen DJ, Carbone D, Piantadosi S, Koga H, Reissman PT, Slamon DJ, Holmes EC, Minna JD. 1990. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Oncogene 5:1603–1610.PubMedGoogle Scholar
  109. 109.
    Suzuki H, Takahashi T, Kuroishi T, Suyama M, Ariyoshi Y, Takahashi T, Ueda R. 1992. p53 mutations in non-small lung cancer in Japan. Association between mutations and smoking. Cancer Res 52:734–736.PubMedGoogle Scholar
  110. 110.
    Miller CW, Simon K, Aslo A, Kok K, Yokota, Buys HCM, Terada M, Koeffler HP. 1992. p53 Mutations in human lung tumors. Cancer Res 52:1695–1698.PubMedGoogle Scholar
  111. 111.
    International Agency for Research on Cancer. 1984. Coke production. IARC Monogr 34:101–131.Google Scholar
  112. 112.
    Castonguay A, Stoner GD, Schut HAJ, Hecht SS. 1983. Metabolism of tobacco-specific N-nitrosamines by cultured human tissues. Proc Natl Acad Sci USA 80:6694–6697.PubMedCrossRefGoogle Scholar
  113. 113.
    Smith TJ, Guo Z, Gonzalez FJ, Guengerich FP, Stoner GD, Yang CS. 1992. Metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in human lung and liver microsomes and cytochromes P-450 expressed in hepatoma cells. Cancer Res 52:1757–1763.PubMedGoogle Scholar
  114. 114.
    Smith TJ, Guo Z, Thomas PE, Chung F-L, Morse MA, Eklind K, Yang CS. 1990. Metabolism of 4-(methylnitrosmino)-1-(3-pyridyl)-1-butanone in mouse lung microsomes and its inhibition by isothiocyanates. Cancer Res 50:6817–6822.PubMedGoogle Scholar
  115. 115.
    Devereux TR, Anderson MW, Belinsky SA. 1988. Factors regulating activation and DNA alkylation of 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone and nitrosodimethylamine in rat lung and isolated lung cells, and the relationship to carcinogenicity. Cancer Res 48:4215–4221.PubMedGoogle Scholar
  116. 116.
    Guo Z, Smith TJ, Ishizaki H, Yang CS. 1991. Metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) by cytochrome P450IIB1 in a reconstituted system. Carcinogenesis 12:2277–2282.PubMedCrossRefGoogle Scholar
  117. 117.
    Hecht SS, Trushin N, Castonguay A, Rivenson A. 1986. Comparative tumorigenicity and DNA methylation in F344 rats by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and N-nitrosodimethylamine. Cancer Res 46:498–502.PubMedGoogle Scholar
  118. 118.
    Murphy SE, Palomino A, Hecht SS, Hoffmann D. 1990. Dose-response study of DNA and hemoglobin adduct formation by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in F344 rats. Cancer Res 50:5446–5452.PubMedGoogle Scholar
  119. 119.
    Hecht SS, Spratt TE, Trushin N. 1988. Evidence for 4-(3-pyridyl)-4-oxobutylation of DNA in F344 rats treated with the tobacco-specific nitrosamines 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and N′-nitrosonornicotine. Carcinogenesis 9:161–165.PubMedCrossRefGoogle Scholar
  120. 120.
    Peterson LA, Hecht SS. 1991. O6-Methylguanine is a critical determinant of 4-(methyl-nitrosamino)-1-(3-pyridyl)-1-butanone tumorigenesis in A/J mouse lung. Cancer Res 51: 5557–5564.PubMedGoogle Scholar
  121. 121.
    Mustonen R, Schoket B, Hemminki K. 1993. Smoking-related DNA adducts: 32P-post-labeling analysis of 7-methylguanine in human bronchial and lymphocyte DNA. Carcinogenesis 14:151–154.PubMedCrossRefGoogle Scholar
  122. 122.
    Carmella SG, Kagan SS, Kagan M, Foiles PG, Palladino G, Quart AM, Quart E, Hecht SS. 1990. Mass spectrometric analysis of tobacco-specific nitrosamine hemoglobin adducts in snuff dippers, smokers, and nonsmokers. Cancer Res 50:5438–5445.PubMedGoogle Scholar
  123. 123.
    Belinsky SA, Devereux TR, White CM, Foley JF, Maronpot RR, Anderson MW. 1991. Role of Clara cells and type II cells in the development of pulmonary tumors in rats and mice following exposure to a tobacco-specific nitrosamine. Exp Lung Res 17:263–278.PubMedCrossRefGoogle Scholar
  124. 124.
    Oreffo VIC, Lin H-W, Padmanabhan R, Witschi HP. 1993. K-ras and p53 point mutations in 4-(methylnitrosamino-1-(3-pyridyl)-1-butanone-induced hamster lung tumors. Carcinogenesis 14:451–455.PubMedCrossRefGoogle Scholar
  125. 125.
    Ronai Z, Gradia S, Peterson LA, Nagao M, Makino H, Hecht SS. 1993. Analysis of K-ras and p53 mutations in lung tumors induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), 4-(acetoxymethylnitrosamino)-1-(3-pyridyl)-1-butanone (NNKOAc) or acetoxy-methylmethylnitrosamine (AMMN). Proc Am Assoc Cancer Res 34:170.Google Scholar
  126. 126.
    Rodenhuis S, Slebos RJC. 1992. Clinical significance of ras oncogene activation in human lung cancer. Cancer Res Suppl. 52:2665s-2669s.Google Scholar
  127. 127.
    Singer B, Essigmann JM. 1991. Site-specific mutagenesis: retrospective and prospective. Carcinogenesis 12:949–955.PubMedCrossRefGoogle Scholar
  128. 128.
    Kiryluk S, Wald N. 1989. Trends in cigarette smoking habits in the United Kingdom. In Nicotine, Smoking and the Low Tar Programme, N Wald and P Froggatt (eds.). Oxford University Press: Oxford, UK, pp. 53–69.Google Scholar
  129. 129.
    Hoffmann D, Hoffmann I, Wynder EL. 1991. Lung cancer and the changing cigarette. IARC Sci Publ 105:449–459.PubMedGoogle Scholar
  130. 130.
    Fischer S, Spiegelhaider B, Preussmann R. 1989. Influence of smoking parameters on the delivery of tobacco-specific nitrosamines in cigarette smoke. A contribution to relative risk evaluation. Carcinogenesis 10:1059–1066.PubMedCrossRefGoogle Scholar
  131. 131.
    Djordjevic MV, Sigountos CW, Brunemann KD, Hoffmann D. 1990. Tobacco-specific nitrosamine delivery in the mainstream smoke of high-and low-yield cigarettes smoked with varying puff volumes. Proc CORESTA Symp, pp. 54–62.Google Scholar
  132. 132.
    Halpern MT, Gillespie BW, Warner KE. 1993. Patterns of absolute risk of lung cancer mortality in former smokers. J Natl Cancer Inst 85:457–464.PubMedCrossRefGoogle Scholar
  133. 133.
    Norman V. 1982. Changes in the smoke chemistry of modern day cigarettes. Recent Adv Tobacco Sci 8:141–177.Google Scholar
  134. 134.
    Norman V. 1974. The effect of perforated tipping paper on the yields of various smoke components. Beitr Tabakforsch 7:282–287.Google Scholar
  135. 135.
    Brunnemann KD, Masaryk J, Hoffmann D. 1983. The role of tobacco stems in the formation of N-nitrosamines in tobacco and mainstream and sidestream smoke. J Agric Food Chem 31:1221–1224.CrossRefGoogle Scholar
  136. 136.
    Safer cigarettes. 1989. New York Times, March 3, p. A38.Google Scholar
  137. 137.
    Kelloff GJ, Boone CW, Malone WF, Steele VE. 1992. Chemoprevention clinical trials. Mutat Res 267:291–295.PubMedCrossRefGoogle Scholar
  138. 138.
    Wattenberg LW. 1992. Inhibition of carcinogenesis by minor dietary constituents. Cancer Res 52:2085s-2091s.Google Scholar
  139. 139.
    Wattenberg LW. 1993. Inhibition of carcinogenesis by nonnutrient constituents in the diet. In Food and Cancer Prevention: Chemical and Biological Aspects, KW Waldron, IT Johnson, and GR Fenwich (eds.). The Royal Society of Chemistry: Cambridge, UK, pp. 12–23.CrossRefGoogle Scholar
  140. 140.
    Morse MA, Wang C-X, Stoner GD, Mandai S, Conran PB, Amin SG, Hecht SS, Chung F-L. 1989. Inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced DNA adduct formation and tumorigenicity in the lung of F344 rats by dietary phenethyl isothiocyanates. Cancer Res 49:549–553.PubMedGoogle Scholar
  141. 141.
    Morse MA, Eklind KI, Amin SG, Hecht SS, Chung F-L. 1989. Effects of alkyl chain length on the inhibition of NNK-induced lung neoplasia in A/J mice by arylalkyl isothiocyanates. Carcinogenesis 10:1757–1759.PubMedCrossRefGoogle Scholar
  142. 142.
    Morse MA, Wang C-X, Amin SG, Hecht SS, Chung F-L. 1988. Effect of dietary sinigrin or indole-3-carbinol on O6-methylguanine-DNA-transmethylase activity and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced DNA methylation and tumorigenicity in F344 rats. Carcinogenesis 9:1891–1895.PubMedCrossRefGoogle Scholar
  143. 143.
    Morse MA, LaGreca SD, Amin SG, Chung F-L. 1990. Effects of indole-3-carbinol on lung tumorigenesis and DNA methylation induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) on the metabolism and disposition of NNK in A/J mice. Cancer Res 2613–2617.Google Scholar
  144. 144.
    Pepin P, Rossignol G, Castonguay A. 1990. Inhibition of NNK-induced lung tumorigenesis in A/J mice by ellagic acid and butylated hydroxyanisole. Cancer J 3:266–273.Google Scholar
  145. 145.
    Wattenberg LW, Coccia JB. 1991. Inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone carcinogenesis in mice by D-limonene and citrus fruit oils. Carcinogenesis 12:115–117.PubMedCrossRefGoogle Scholar
  146. 146.
    Hong J-Y, Wang ZY, Smith TJ, Zhou S, Shi S, Pan J, Yang CS. 1992. Inhibitory effects of diallyl sulfide on the metabolism and tumorigenicity of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in A/J mouse lung. Carcinogenesis 13:901–904.PubMedCrossRefGoogle Scholar
  147. 147.
    El-Bayoumy K, Upadhyaya P, Dcsai DH, Amin S, Hecht SS. 1993. Inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone tumorigenicity in mouse lung by the synthetic organoselenium compound, 1,4-phenylenebis(methylene)seleno-cyanate. Carcinogenesis 14:1111–1113.PubMedCrossRefGoogle Scholar
  148. 148.
    Hoffmann D, Rivenson A, Abbi R, Wynder EL. 1993. A study of tobacco carcinogenesis L. Effect of the fat content of the diet on the carcinogenic activity of 4-(methylnitrosamino)-1-(3-pyridyl)-butanone in F344 rats. Cancer Res 53:2758–2761.PubMedGoogle Scholar
  149. 149.
    Wynder EL, Hebert JR, Kabat GC. 1987. Association of dietary fat and lung cancer. J Natl Cancer Inst 79:631–637.PubMedGoogle Scholar
  150. 150.
    Hebert JR, Kabat GC. 1991. Distribution of smoking and its association with lung cancer: implications for studies on the association of fat with cancer. J Natl Cancer Inst 83:872–874.PubMedCrossRefGoogle Scholar
  151. 151.
    Xie JX, Lesaffre E, Kasteloot H. 1991. The relationship between animal fat intake, cigarette smoking and lung cancer. Cancer Cause Control 2:79–83.CrossRefGoogle Scholar
  152. 152.
    Goodman MF, Hankin JH, Wilkens LR, Kolonel LN. 1992. High-fat foods and the risk of lung cancer. Epidemiology 3:288–299.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1994

Authors and Affiliations

  • Dietrich Hoffmann
  • Ilse Hoffmann

There are no affiliations available

Personalised recommendations